



Holista CollTech Limited

(ASX:HCT / ABN 24 094 515 992)

283 Rokeby Road Subiaco WA 6008

P: +61 8 6141 3500; F: +61 8 6141 3599 W:

www.holistaco.com

ASX Announcement

16 March 2020

COMMENCEMENT OF TESTS IN U.K. LAB OF PATHAWAY®'S EFFICACY AGAINST COVID-19 AND OTHER CORONAVIRUSES; RESULTS EXPECTED IN 2-3 WEEKS

KUALA LUMPUR/PERTH, 16 MARCH 2020 – **Holista CollTech** (ASX:HCT, “Holista”) refers to its previous announcements in relation to NatShield™, a hand-held sanitiser developed by the company and a nasal sanitising balm being developed which use Path-Away®, the all-natural active ingredient. Holista has global distribution of the plant-based Path-Away® sold as a sanitiser under the trademark of NatShield™, developed by Global Infections Control Consultants LLC (“GICC LLC”), which has been proven as an effective broad-spectrum sanitiser. GICC LLC is headquartered in Bluffton, South Carolina in the United States.

Holista is pleased to announce that in collaboration with GICC LCC it commenced testing Path-Away® at a leading microbiology laboratory in the United Kingdom on 12 March 2020. The tests will determine Path-Away®'s efficacy as a sanitiser against Covid-19, the coronavirus that has infected over 146,000 and killed at least 5,400 people globally as at 13 March 2020. The tests, expected to be completed before the end of April 2020, are based on all accepted testing protocols needed to provide data for Holista and GICC LCC to make label claims specific to Covid-19, which was formerly referred to as “2019 novel coronavirus” or “2019-nCoV”.

The testing panel will also include other members of the coronavirus family such as SARS and the more common human influenza virus.

Coronaviruses (“CoVs”) are positive-stranded RNA enveloped viruses with a crown-like appearance under an electron microscope. Members of this large family of viruses can cause respiratory, enteric, hepatic, and neurological diseases in different animal species, including camels, cattle, cats, and bats. To date, seven human CoVs (“HCoVs”) — capable of infecting humans — have been identified.

“Since the start of the year we have accorded testing against Covid-19 as a top priority. However, the situation in China until recent days had led to delays in obtaining samples of the coronavirus and there was the issue of high security around the testing facilities. As such, we are really pleased testing has commenced in a globally recognised laboratory,” said Dr. Rajen Manicka, CEO of Holista.

“This testing at an approved laboratory in the United Kingdom is an important breakthrough. Path-Away® has had success before Covid-19, but in view of the scale and urgency of the problem worldwide caused by Covid-19, we need to obtain verifiable data that Path-Away® kills this coronavirus. I am personally coordinating with the laboratory which has placed testing of Covid-19 on high priority,” said Dr. Arthur V. Martin President of GICC.

This announcement has been approved for release by all members of the Holista Board.

Authorised by:

Dr Rajen Manicka
Managing Director

#END#

About Holista CollTech Ltd

Holista CollTech Ltd (“Holista”) is a natural wellness company, the result of a merger between Holista Biotech Sdn Bhd and CollTech Australia Ltd. The company has 3 main divisions:

- Dietary supplements and personal care
- Food Ingredients – a patented blend that can make most baked foods become low glycemic
- Ovine collagen – suitable as cosmetic, food, and research- grade collagen

Listed on the Australian Securities Exchange (“ASX”), Holista researches, develops, manufactures and markets “health-style” products to address the unmet and evolving needs of natural nutrition and medicine. Holista’s suite of ingredients includes low-GI baked products, reduced-sodium salts, low-fat fried foods and low-calorie sugar without compromising taste, odour and mouthfeel. Holista remains the only company to produce sheep (ovine) collagen using patented extraction methods.

For more information, please refer to <http://www.holistaco.com>

For further information, please contact:

Corporate Affairs & Business Opportunities

Dr Rajen Manicka: rajen.m@holistaco.com

General Enquiries: enquiries@holistaco.com

Australia

283 Rokeby Road

Subiaco WA 6008

P: +61 8 6141 3500 ; F: +61 8 6141 3599

Malaysia

12th Floor, Amcorp Trade Centre, PJ Tower

No. 18, Persiaran Barat off Jalan Timur

46000, Petaling Jaya, Malaysia

P: +603 7965 2828 ; F: +603 7965 2777

Media and Investor Relations Enquiries

WeR1 Consultants Pte Ltd

3 Phillip Street #12-01

Singapore 048693

E: holista@wer1.net; P: +65 67374844